Bromodomain and Extra Terminal (BET) Inhibitor Suppresses Macrophage-Driven Steroid-Resistant Exacerbations of Airway Hyper-Responsiveness and Inflammation
Thi Hiep Nguyen(University of Newcastle Australia), Ming Yang(Fujian Medical University)
Cited by 23
Related Papers
Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence From PROSPERO, A Prospective Real-World Study
|The Journal of Allergy and Clinical Immunology In Practice|2018|277
The XTEND-CIU study: Long-term use of omalizumab in chronic idiopathic urticaria
|Journal of Allergy and Clinical Immunology|2017|89